메뉴 건너뛰기




Volumn 25, Issue 2, 2015, Pages 164-168

Erythropoiesis-stimulating agents: Dose and mortality risk

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT;

EID: 84925131696     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2014.10.012     Document Type: Review
Times cited : (13)

References (23)
  • 1
    • 32944465862 scopus 로고    scopus 로고
    • Managing a fateful alliance: anaemia and cardiovascular outcomes
    • Eckardt K.U. Managing a fateful alliance: anaemia and cardiovascular outcomes. Nephrol Dial Transplant 2005, 20(suppl 6):vi16-vi20.
    • (2005) Nephrol Dial Transplant , vol.20 , pp. vi16-vi20
    • Eckardt, K.U.1
  • 2
    • 0034765367 scopus 로고    scopus 로고
    • Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%
    • Collins A.J., Li S., St Peter W., et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 2001, 12:2465-2473.
    • (2001) J Am Soc Nephrol , vol.12 , pp. 2465-2473
    • Collins, A.J.1    Li, S.2    St Peter, W.3
  • 3
    • 33645474065 scopus 로고    scopus 로고
    • Association between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients
    • Regidor D.L., Kopple J.D., Kovesdy C.P., et al. Association between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006, 17:1181-1191.
    • (2006) J Am Soc Nephrol , vol.17 , pp. 1181-1191
    • Regidor, D.L.1    Kopple, J.D.2    Kovesdy, C.P.3
  • 4
    • 0032572913 scopus 로고    scopus 로고
    • The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin
    • Besarab A., Bolton W.K., Browne J.K., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998, 339(suppl 9):584-590.5.
    • (1998) N Engl J Med , vol.339 , pp. 584-590.5
    • Besarab, A.1    Bolton, W.K.2    Browne, J.K.3
  • 5
    • 33750983605 scopus 로고    scopus 로고
    • CHOIR investigators: correction of anemia with epoetin alfa in chronic kidney disease
    • Singh A.K., Szczech L., Tang K.L., et al. CHOIR investigators: correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006, 355:2085-2098.
    • (2006) N Engl J Med , vol.355 , pp. 2085-2098
    • Singh, A.K.1    Szczech, L.2    Tang, K.L.3
  • 6
    • 33751002326 scopus 로고    scopus 로고
    • Normalization of Hb level in patients with chronic kidney disease and anemia
    • Drüeke T.B., Locatelli F., Clyne N., et al. Normalization of Hb level in patients with chronic kidney disease and anemia. N Engl J Med 2006, 355(suppl 20):2071-2084. CREATE Investigators.
    • (2006) N Engl J Med , vol.355 , pp. 2071-2084
    • Drüeke, T.B.1    Locatelli, F.2    Clyne, N.3
  • 7
    • 33846669860 scopus 로고    scopus 로고
    • Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis
    • Phrommintikul A., Haas S.J., Elsik M., Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007, 369:381-388.
    • (2007) Lancet , vol.369 , pp. 381-388
    • Phrommintikul, A.1    Haas, S.J.2    Elsik, M.3    Krum, H.4
  • 8
    • 70949108082 scopus 로고    scopus 로고
    • A trial of darbopoetin alfa in type 2 diabetes and chronic kidney disease
    • Pfeffer M.A., Burdmann E.A., Chen C.Y., et al. A trial of darbopoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009, 361:2019-2032. TREAT Investigators.
    • (2009) N Engl J Med , vol.361 , pp. 2019-2032
    • Pfeffer, M.A.1    Burdmann, E.A.2    Chen, C.Y.3
  • 9
    • 77957311438 scopus 로고    scopus 로고
    • Conversion of darbepoetin to low doses of CERA maintains Hb levels in non-dialysis chronic kidney disease patients
    • Minutolo R., Zamboli P., Chiodini P., et al. Conversion of darbepoetin to low doses of CERA maintains Hb levels in non-dialysis chronic kidney disease patients. Blood Purif 2010, 30:186-194.
    • (2010) Blood Purif , vol.30 , pp. 186-194
    • Minutolo, R.1    Zamboli, P.2    Chiodini, P.3
  • 10
    • 80053913535 scopus 로고    scopus 로고
    • Prognosis of CKD patients receiving outpatient nephrology care in Italy
    • De Nicola L., Chiodini P., Zoccali C., et al. Prognosis of CKD patients receiving outpatient nephrology care in Italy. Clin J Am Soc Nephrol 2011, 6:2421-2428. SIN-TABLE CKD Study Group.
    • (2011) Clin J Am Soc Nephrol , vol.6 , pp. 2421-2428
    • De Nicola, L.1    Chiodini, P.2    Zoccali, C.3
  • 11
    • 77955722809 scopus 로고    scopus 로고
    • Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease
    • Palmer S.C., Navaneethan S.D., Craig J.C., et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 2010, 153:23-33.
    • (2010) Ann Intern Med , vol.153 , pp. 23-33
    • Palmer, S.C.1    Navaneethan, S.D.2    Craig, J.C.3
  • 12
    • 77956704796 scopus 로고    scopus 로고
    • Erythropoietic response and outcomes in kidney disease and type 2 diabetes
    • Solomon S.D., Uno H., Lewis E.F., et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 2010, 363:1146-1155. Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Investigators.
    • (2010) N Engl J Med , vol.363 , pp. 1146-1155
    • Solomon, S.D.1    Uno, H.2    Lewis, E.F.3
  • 13
    • 84155164794 scopus 로고    scopus 로고
    • Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with darboetin alfa: the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) experience
    • Skali H., Parving H.H., Parfrey P.S., et al. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with darboetin alfa: the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) experience. Circulation 2011, 124:2903-2908.
    • (2011) Circulation , vol.124 , pp. 2903-2908
    • Skali, H.1    Parving, H.H.2    Parfrey, P.S.3
  • 14
    • 16844375873 scopus 로고    scopus 로고
    • Distribution of C-reactive protein values in the United States
    • Woloshin S., Schwartz L.M. Distribution of C-reactive protein values in the United States. N Engl J Med 2005, 352:1611-1613.
    • (2005) N Engl J Med , vol.352 , pp. 1611-1613
    • Woloshin, S.1    Schwartz, L.M.2
  • 15
    • 79958180106 scopus 로고    scopus 로고
    • Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study
    • Panichi V., Rosati A., Bigazzi R., et al. Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study. Nephrol Dial Transplant 2011, 26:2641-2648. RISCAVID Study Group.
    • (2011) Nephrol Dial Transplant , vol.26 , pp. 2641-2648
    • Panichi, V.1    Rosati, A.2    Bigazzi, R.3
  • 16
    • 83655163838 scopus 로고    scopus 로고
    • Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the dialysis registry in Japan
    • Fukuma S., Yamaguchi T., Hashimoto S., et al. Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the dialysis registry in Japan. Am J Kidney Dis 2012, 59:108-116.
    • (2012) Am J Kidney Dis , vol.59 , pp. 108-116
    • Fukuma, S.1    Yamaguchi, T.2    Hashimoto, S.3
  • 17
    • 84871247763 scopus 로고    scopus 로고
    • Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis
    • Koulouridis I., Alfayez M., Trikalinos T.A., Balk E.M., Jaber B.L. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am J Kidney Dis 2013, 61:44-56.
    • (2013) Am J Kidney Dis , vol.61 , pp. 44-56
    • Koulouridis, I.1    Alfayez, M.2    Trikalinos, T.A.3    Balk, E.M.4    Jaber, B.L.5
  • 18
    • 0030008101 scopus 로고    scopus 로고
    • Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients
    • Braun J., Oldendorf M., Moshage W., Heidler R., Zeitler E., Luft F.C. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 1996, 27:394-401.
    • (1996) Am J Kidney Dis , vol.27 , pp. 394-401
    • Braun, J.1    Oldendorf, M.2    Moshage, W.3    Heidler, R.4    Zeitler, E.5    Luft, F.C.6
  • 20
    • 79955624020 scopus 로고    scopus 로고
    • Progression of aortic calcification is associated with disorders of mineral metabolism and mortality in chronic dialysis patients
    • Noordzij M., Cranenburg E.M., Engelsman L.F., et al. Progression of aortic calcification is associated with disorders of mineral metabolism and mortality in chronic dialysis patients. Nephrol Dial Transplant 2011, 26:1662-1669. NECOSAD Study Group.
    • (2011) Nephrol Dial Transplant , vol.26 , pp. 1662-1669
    • Noordzij, M.1    Cranenburg, E.M.2    Engelsman, L.F.3
  • 21
    • 80052561697 scopus 로고    scopus 로고
    • Arterial calcification in chronic kidney disease: key roles for calcium and phosphate
    • Shanahan C.M., Crouthamel M.H., Kapustin A., Giachelli C.M. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res 2011, 109:697-711.
    • (2011) Circ Res , vol.109 , pp. 697-711
    • Shanahan, C.M.1    Crouthamel, M.H.2    Kapustin, A.3    Giachelli, C.M.4
  • 22
    • 0042885985 scopus 로고    scopus 로고
    • Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality
    • London G.M., Guerin A.P., Marchais S.J., Métivier F., Pannier B., Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003, 18:1731-1740.
    • (2003) Nephrol Dial Transplant , vol.18 , pp. 1731-1740
    • London, G.M.1    Guerin, A.P.2    Marchais, S.J.3    Métivier, F.4    Pannier, B.5    Adda, H.6
  • 23
    • 77954594687 scopus 로고    scopus 로고
    • Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (C.E. DOSE) trial protocol
    • Strippoli G.F. Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (C.E. DOSE) trial protocol. Trials 2010, 11:70. Clinical Evaluation of the DOse of Erythropoietins Study Group (C.E. DOSE).
    • (2010) Trials , vol.11 , pp. 70
    • Strippoli, G.F.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.